samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Klöckner Pentaplast Launches Its New Recyclable PET Blister Film

Klöckner Pentaplast



London, UK – 24th AUGUST 2021
– Klöckner Pentaplast (kp), a leading global manufacturer of high barrier protective packaging solutions with industry-leading use of recycled content material, has launched kpNext, its first-to-market innovation in recyclable PET blister films. kpNext is the only PET recyclable blister that is completely compatible on pharmaceutical manufacturing form, fill and seal equipment.

kp has a rich history of innovative pharmaceutical blister packaging solutions and kpNextׄ is the next step of that evolution. Not only is kpNext the only PET film designed to be a recyclable blister package, but it does not come at the expense of the manufacturing process. Pharmaceutical companies and converters can utilise kpNext on their existing form, fill and seal lines with no loss of line speed or a need to retool. It truly is the best of both worlds, a sustainable yet functional solution.

From consumers to global brands to governments, the demand for recyclable packaging has never been higher. kpNext answers those calls. It is produced from a globally recyclable material and is designed to be recycled in the RIC (resin identification code) #1 PET stream.

Daniel Stagnaro, Head of Technology stated: “Current pharmaceutical blister packaging is classified as RIC #7, produced from a multi material structure, which is not recyclable and therefore is disposed in a landfill or incinerated. Major pharmaceutical companies have been challenging blister manufacturers for a solution that is responsible and recyclable. kp has answered those challenges with kpNext.”

kpNext is the culmination of three years’ worth of research and development. Utilising its kp i.center, an application development lab located in Charlottesville, VA, kp scientists, chemists and technical teams have worked on developing the technology to where it is today: A blister film designed to be fully recyclable and a plug & play solution on existing pharmaceutical lines.

At launch, Dr. Jorg Schneewind, President of kp’s PHD Division said: “kpNext is an example of excellence in product innovation because it has been designed to be recyclable and is a seamless transition, taking the burden off our customers to adapt to the sustainable film. Instead, the film adapted to the equipment. It’s a true milestone for the industry and for kp - in our ability to support our customers in meeting their sustainability commitments.”

“For over 55 years, kp has been at the forefront of sustainable packaging designs, championing the circular economy and closed-loop recycling while leading in innovative, recycled-content products,” said Scott Tracey, CEO of Klöckner Pentaplast. “As a company, we’re committed to taking every opportunity to make packaging recyclable. A win-win for our long-term partners.”

kpNext - Tomorrow is finally here, and it’s crystal clear
phone +49.2602.915.0
web www.kpfilms.com/en/
email Klöckner Pentaplast Group, P.O. Box 11 65 56401, Montabaur
 
Print this page
Send to a friend
   
spacer
News and Press Releases

New Natoli Tablet Press & Tooling Training Scheduled

ST. CHARLES, MO (May 9, 2022) — For years, one of Natoli Engineering’s competitive advantage has been our broad array of training courses. Where many companies only sell tablet press tooling and machinery, Natoli offers in-house training seminars that give our customers an opportunity to learn how to operate and maintain the equipment to peak performance.
More info >>


White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

Industry Events

Connect in Pharma

14-15 September 2022, Plaexpo, Geneva, Switzerland

The new event driving innovation for pharma and biopharma businesses, Connect in Pharma will unite key players in Pharmaceutical and Biopharmaceutical packaging and production in Geneva on 14 – 15 September 2022.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement